Meanwhile, Unilife has pricked early investor optimism over commercialising its retractable syringe with a $29.7m loss ($14.5m when adjusted for non-cash items). A $9.7m shortfall ($5.7m adjusted) was incurred in the fourth quarter.
To be fair, Unilife, which is now domiciled in the US, is in the early stages of a supply deal with Sanofi-Aventis (the biggest purchaser of pre-filled syringes). So, full revenues are yet to flow and the timing depends on milestone payments. Still, investors knocked 5 per cent off the share price.
UNS Price at posting:
93.0¢ Sentiment: LT Buy Disclosure: Not Held
